HomeCompareMNMD vs CL

MNMD vs CL: Dividend Comparison 2026

MNMD yields 10.58% · CL yields 2.43%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CL wins by $567.00 in total portfolio value· pulled ahead in Year 10
10 years
MNMD
MNMD
● Live price
10.58%
Share price
$18.91
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.2K
Annual income
$2,053.05
Full MNMD calculator →
CL
CL
● Live price
2.43%
Share price
$85.73
Annual div
$2.08
5Y div CAGR
28.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.8K
Annual income
$5,401.96
Full CL calculator →

Portfolio growth — MNMD vs CL

📍 CL pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMNMDCL
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MNMD + CL cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MNMD pays
CL pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MNMD
Annual income on $10K today (after 15% tax)
$899.00/yr
After 10yr DRIP, annual income (after tax)
$1,745.09/yr
CL
Annual income on $10K today (after 15% tax)
$206.23/yr
After 10yr DRIP, annual income (after tax)
$4,591.67/yr
At 15% tax rate, CL beats the other by $2,846.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MNMD + CL for your $10,000?

MNMD: 50%CL: 50%
100% CL50/50100% MNMD
Portfolio after 10yr
$40.5K
Annual income
$3,727.50/yr
Blended yield
9.20%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CL right now

MNMD
Analyst Ratings
1
Buy
Consensus: Buy
Price Target
$28.00
+48.1% upside vs current
Range: $28.00 — $28.00
Altman Z
5.2
Piotroski
2/9
CL
Analyst Ratings
17
Buy
24
Hold
2
Sell
Consensus: Hold
Price Target
$92.45
+7.8% upside vs current
Range: $85.00 — $100.00
Altman Z
4.5
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MNMD buys
0
CL buys
0
No recent congressional trades found for MNMD or CL in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMNMDCL
Forward yield10.58%2.43%
Annual dividend / share$2.00$2.08
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28.6%
Portfolio after 10y$40.2K$40.8K
Annual income after 10y$2,053.05$5,401.96
Total dividends collected$15.5K$18.0K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold
Analyst price target$28.00$92.45

Year-by-year: MNMD vs CL ($10,000, DRIP)

YearMNMD PortfolioMNMD Income/yrCL PortfolioCL Income/yrGap
1$11,758$1,057.64$11,012$312.01+$746.00MNMD
2$13,743$1,162.18$12,196$412.95+$1.5KMNMD
3$15,974$1,269.54$13,599$549.66+$2.4KMNMD
4$18,472$1,379.15$15,288$736.64+$3.2KMNMD
5$21,255$1,490.43$17,353$995.28+$3.9KMNMD
6$24,346$1,602.82$19,926$1,357.80+$4.4KMNMD
7$27,766$1,715.78$23,194$1,873.82+$4.6KMNMD
8$31,538$1,828.79$27,439$2,621.52+$4.1KMNMD
9$35,687$1,941.36$33,088$3,727.38+$2.6KMNMD
10← crossover$40,239$2,053.05$40,806$5,401.96$567.00CL

MNMD vs CL: Complete Analysis 2026

MNMDStock

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Full MNMD Calculator →

CLConsumer Staples

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products worldwide. The company operates through two segments, Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items. This segment markets and sells its products under various brands, which include Colgate, Darlie, elmex, hello, meridol, Sorriso, Tom's of Maine, Irish Spring, Palmolive, Protex, Sanex, Softsoap, Lady Speed Stick, Speed Stick, EltaMD, Filorga, PCA SKIN, Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, and Cuddly to a range of traditional and eCommerce retailers, wholesalers, and distributors. It also includes pharmaceutical products for dentists and other oral health professionals. The Pet Nutrition segment offers pet nutrition products for everyday nutritional needs under the Hill's Science Diet brand; and a range of therapeutic products to manage disease conditions in dogs and cats under the Hill's Prescription Diet brand. This segment markets and sells its products through pet supply retailers, veterinarians, and eCommerce retailers. Colgate-Palmolive Company was founded in 1806 and is headquartered in New York, New York.

Full CL Calculator →
📬

Get this MNMD vs CL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MNMD vs SCHDMNMD vs JEPIMNMD vs OMNMD vs KOMNMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.